首頁 > 市場調查報告書 > 製藥

藥物開發開發業務受託機關

市場調查報告書

商品編碼

1900697

藥物研發外包市場規模、佔有率及成長分析（按藥物類型、治療領域、最終用戶及地區分類）－2026-2033年產業預測

Drug Discovery Outsourcing Market Size, Share, and Growth Analysis, By Drug Type (Small Molecules, Large Molecules), By Therapeutics Area (Oncology, Diabetes), By End User,, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月18日 | 出版商:

SkyQuest | 英文 242 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，藥物研發外包市場規模將達到 38.6 億美元，到 2025 年將達到 41.4 億美元，到 2033 年將達到 72.2 億美元，在預測期（2026-2033 年）內，複合年成長率為 7.2%。

由於外包成本高且監管嚴格，藥物研發外包市場面臨許多挑戰。然而，癌症和慢性病發病率上升、人口老化、法律環境趨於寬鬆，以及開發中國家）更容易獲得價格合理且技能精湛的勞動力等因素，都為市場提供了成長機會。行業相關人員正在調整策略，以在不斷變化的環境中保持市場佔有率。製藥業正經歷重大變革，包括向生物製藥的轉型和專利到期，這些都正在改變傳統的商業模式。透過專注於先導化合物確認和先導藥物最適化等階段的專業化，企業可以增強其核心競爭力。研發投入的成長、對創新藥物研發方法的需求以及人工智慧等技術的進步，都在加速外包趨勢的發展。

藥物研發外包市場按工作流程、治療領域、藥物類型、服務類型、最終用戶和地區進行細分。依工作流程分類，市場分為標靶識別和篩檢、標靶檢驗和功能資訊學、先導化合物識別和候選藥物最佳化、臨床前開發等相關工作流程。依治療領域分類，市場分為呼吸系統、疼痛和麻醉、腫瘤、眼科、循環系統、心臟病學、內分泌學、胃腸病學、免疫調節、抗感染、中樞神經系統、皮膚病學和泌尿生殖系統。依藥物類型分類，市場分為小分子藥物和大分子藥物（生物製藥）。按服務類型分類，市場分為化學服務和生物學服務。按最終用戶分類，市場分為製藥和生技公司、學術機構和其他機構。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

藥物研發外包市場促進因素

製藥業日益成長的成本削減需求是藥物研發外包市場發展的關鍵促進因素。該行業的公司不斷尋求最佳化營運並增加研發投入。透過將標靶分子鑑定、篩檢、先導化合物最佳化和臨床前試驗等藥物研發活動外包給外部合作夥伴，製藥公司可以大幅降低庫存、人事費用和管理費用。這種方式不僅使他們能夠獲得受託研究機構(CRO) 提供的先進技術、一流設施和專業知識，還能加速藥物研發進程。最終，這種模式能夠帶來顯著且永續的營運和財務優勢，從而在生物製藥行業中得到廣泛應用。

藥物研發外包市場的限制因素

由於監管和合規風險可能阻礙成長，藥物研發外包市場面臨嚴峻挑戰。各國在臨床試驗、資料管理和產品開發方面的監管要求存在差異，這為企業帶來了許多障礙。嚴格遵守良好實驗室規範 (GLP) 和良好臨床規範 (GCP) 等標準對於預防監管問題和確保藥物研發流程的完整性至關重要。此外，遵守這些法規的複雜性和耗時性可能會使一些企業放棄外包方案，從而影響整體市場擴張和參與度。

藥物研發外包市場趨勢

受基因療法和細胞療法等創新療法在治療複雜慢性疾病方面日益顯著的療效推動，生物製藥領域的藥物研發外包市場正呈現顯著成長。生物製藥公司逐漸意識到自身研發能力的局限性，並開始尋求專業CRO（合約委外研發機構）和CDMO（合約開發和受託製造廠商）的協助。這一趨勢凸顯了市場對客製化外包服務的日益成長的需求，這些服務能夠簡化藥物研發流程、提高產品品質並縮短上市時間。生物製藥外包的興起反映了該行業致力於在快速變化的醫療環境中推動治療方法的進步。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Charles River Laboratories International, Inc.
WuXi AppTec Co., Ltd.
Laboratory Corporation of America Holdings（LabCorp）
Evotec SE
Covance Inc.
Thermo Fisher Scientific Inc.
Eurofins Scientific
Pharmaron Beijing Co., Ltd.
Syngene International Ltd.
Genscript Biotech Corporation
ChemPartner
Jubilant Biosys Ltd.
ICON plc
QuintilesIMS（IQVIA）
Cambrex Corporation
Viva Biotech
Domainex Ltd.
Curia Global, Inc.（formerly Albany Molecular Research, Inc.）
Tecan Group Ltd.
Shanghai Medicilon Inc.

簡介目錄

Product Code: SQMIG35C2011

Drug Discovery Outsourcing Market size was valued at USD 3.86 Billion in 2024 and is poised to grow from USD 4.14 Billion in 2025 to USD 7.22 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The drug discovery outsourcing market is facing challenges due to high outsourcing costs and stringent regulations. However, emerging opportunities exist, particularly in developing countries, where factors like rising incidences of cancer and chronic diseases, an aging population, a more favorable legal environment, and access to affordable, skilled labor with advanced knowledge present avenues for growth. Industry professionals are adapting strategies to maintain market share amid the evolving landscape. The pharmaceutical sector has experienced significant transformations, with shifts in biopharmaceuticals and patent expirations impacting traditional models. By focusing on specialization in stages like hit confirmation and lead optimization, companies can enhance core competencies. The increasing R&D costs and demand for innovative drug discovery methods, alongside advancements like AI, are propelling the trend toward outsourcing.

Top-down and bottom-up approaches were used to estimate and validate the size of the Drug Discovery Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Drug Discovery Outsourcing Market Segments Analysis

Drug Discovery Outsourcing Market is segmented by Workflow, Therapeutics Area, Drug Type, Service Type, End User, and region. Based on Workflow, the market is segmented into Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Other Associated Workflow. Based on Therapeutics Area, the market is segmented into Respiratory system, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-infective, Central Nervous System, Dermatology, and Genitourinary System. Based on Drug Type, the market is segmented into Small Molecules, Large Molecules (Biopharmaceuticals). Based on Service Type, the market is segmented into Chemistry Services, Biology Services. Based on End User, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Drug Discovery Outsourcing Market

The growing need to minimize costs in the pharmaceutical sector is a significant driver for the drug discovery outsourcing market. Companies in this industry continually strive to optimize their operations and enhance their research and development investments. By delegating drug discovery tasks such as target identification, screening, lead optimization, and preclinical testing to external partners, pharmaceutical firms can considerably lower their inventory, labor, and overhead expenses. This approach not only grants access to the advanced technology, cutting-edge equipment, and specialized knowledge offered by contract research organizations, but also accelerates the drug discovery process. Ultimately, this model delivers substantial and enduring operational and financial advantages that facilitate its acceptance within the biopharmaceutical landscape.

Restraints in the Drug Discovery Outsourcing Market

The Drug Discovery Outsourcing market faces significant challenges due to regulatory and compliance risks that can hinder its growth. Variations in regulatory requirements across countries for clinical trials, data management, and product development create obstacles for companies. Adhering to strict standards, such as Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), is crucial to prevent regulatory issues and ensure the integrity of the drug development process. Additionally, the complexity and time-consuming nature of navigating these regulations can deter some companies from pursuing outsourcing options, thereby affecting overall market expansion and participation.

Market Trends of the Drug Discovery Outsourcing Market

The drug discovery outsourcing market is experiencing a significant shift toward biopharmaceutical outsourcing, driven by the increasing efficacy of innovative therapies such as gene and cell-based treatments for complex chronic diseases. As biopharmaceutical companies recognize their limitations in in-house product development capabilities, they are seeking the expertise of specialized Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs). This trend underscores a growing demand for tailored outsourcing services that streamline the drug discovery process, enhance product quality, and reduce time to market. The evolution towards biopharmaceutical outsourcing reflects the industry's commitment to advancing therapeutics in a rapidly changing healthcare landscape.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Regulatory Analysis
Case Study Analysis

Drug Discovery Outsourcing Market, By Workflow

Market Overview
Target Identification & Screening
Target Validation & Functional Informatics
Lead Identification & Candidate Optimization
Preclinical Development
Other Associated Workflow

Drug Discovery Outsourcing Market, By Therapeutics Area

Market Overview
Respiratory system
Pain and Anesthesia
Oncology
Ophthalmology
Hematology
Cardiovascular
Endocrine
Gastrointestinal
Immunomodulation
Anti-infective
Central Nervous System
Dermatology
Genitourinary System

Drug Discovery Outsourcing Market, By Drug Type

Market Overview
Small Molecules
Large Molecules (Biopharmaceuticals)

Drug Discovery Outsourcing Market, By Service Type

Market Overview
Chemistry Services
Biology Services

Drug Discovery Outsourcing Market, By End User

Market Overview
Pharmaceutical & Biotechnology companies
Academic Institutes
Others

Drug Discovery Outsourcing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Charles River Laboratories International, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laboratory Corporation of America Holdings (LabCorp)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Covance Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharmaron Beijing Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syngene International Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genscript Biotech Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ChemPartner
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Biosys Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QuintilesIMS (IQVIA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cambrex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viva Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Domainex Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Curia Global, Inc. (formerly Albany Molecular Research, Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tecan Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Medicilon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments